Literature DB >> 16806409

Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting.

Paul A Gurbel1, Kevin P Bliden, Kirk Guyer, Nikhil Aggarwal, Udaya S Tantry.   

Abstract

BACKGROUND: We have previously demonstrated that clopidogrel reduces platelet activation and aggregation in patients undergoing stenting. However, the effect of the clopidogrel loading dose on the rate of thrombin-induced platelet-fibrin clot formation is unknown in this patient population. METHODS AND
RESULTS: Using thrombelastography (TEG) we measured the time to platelet-fibrin clot formation (R), a marker of the speed of thrombin generation, in 120 patients undergoing elective coronary artery stenting treated with standard and high loading doses of clopidogrel. Platelet reactivity to adenosine diphosphate (ADP) by light transmittance aggregometry (LTA) was determined simultaneously. Measurements were made immediately before and at 24 h after clopidogrel treatment. Clopidogrel produced a prolongation in R (4.4+/-1.4 min pre vs. 5.4+/-1.7 min post, p<0.001) that directly correlated with the change in platelet aggregation (r=0.65, p<0.0001). Prolongation in R was greatest in patients treated with a high loading dose (p=0.004).
CONCLUSIONS: Delayed thrombin-induced platelet-fibrin clot formation as measured by TEG is a newly reported dose-related effect of clopidogrel that may contribute to the overall antithrombotic properties of the drug in patients undergoing stenting. This effect was more marked in patients loaded with 600 mg, lending further mechanistic support for this dose of clopidogrel as a more effective antithrombotic regimen than the standard 300 mg dose. Measurement of R may serve as a new indicator of clopidogrel responsiveness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806409     DOI: 10.1016/j.thromres.2006.05.006

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

1.  Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation.

Authors:  José L Ferreiro; Masafumi Ueno; Antonio Tello-Montoliu; Salvatore D Tomasello; Davide Capodanno; Piera Capranzano; Kodlipet Dharmashankar; Andrew Darlington; Bhaloo Desai; Fabiana Rollini; Luis A Guzman; Theodore A Bass; Dominick J Angiolillo
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

2.  Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.

Authors:  Fabiana Rollini; Francesco Franchi; Jung Rae Cho; Christopher Degroat; Mona Bhatti; Elisabetta Ferrante; Ronakkumar Patel; Andrew Darlington; Antonio Tello-Montoliu; Bhaloo Desai; Joséluis Ferreiro; Ana Muniz-Lozano; Martin M Zenni; Luis A Guzman; Theodore A Bass; Dominick J Angiolillo
Journal:  J Cardiovasc Transl Res       Date:  2014-01-07       Impact factor: 4.132

3.  Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events.

Authors:  Paul A Gurbel; Kevin P Bliden; Irene A Navickas; Elizabeth Mahla; Joseph Dichiara; Thomas A Suarez; Mark J Antonino; Udaya S Tantry; Eli Cohen
Journal:  Am Heart J       Date:  2010-08       Impact factor: 4.749

4.  Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients.

Authors:  Eli I Lev; Kevin P Bliden; Young-Hoon Jeong; Shachi Pandya; Kelly Kang; Christopher Franzese; Udaya S Tantry; Paul A Gurbel
Journal:  J Am Heart Assoc       Date:  2014-10-20       Impact factor: 5.501

5.  Orthostatic Challenge Shifts the Hemostatic System of Patients Recovered from Stroke toward Hypercoagulability.

Authors:  Gerhard Cvirn; Markus Kneihsl; Christine Rossmann; Margret Paar; Thomas Gattringer; Axel Schlagenhauf; Bettina Leschnik; Martin Koestenberger; Erwin Tafeit; Gilbert Reibnegger; Irhad Trozic; Andreas Rössler; Franz Fazekas; Nandu Goswami
Journal:  Front Physiol       Date:  2017-02-07       Impact factor: 4.566

6.  Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients.

Authors:  Daye Cheng; Shuo Zhao; Yiwen Hao
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

7.  Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease.

Authors:  Renske H Olie; Paola E J van der Meijden; Henri M H Spronk; Rene van Oerle; Stale Barvik; Vernon V S Bonarjee; Hugo Ten Cate; Dennis W T Nilsen
Journal:  TH Open       Date:  2019-08-16

8.  Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study.

Authors:  Joanna J Wykrzykowska; Ascan Warnholtz; Peter de Jaeger; Nick Curzen; Keith G Oldroyd; Jean Philippe Collet; Jurrien M Ten Berg; Tessa Rademaker; Dick Goedhart; Jurgen Lissens; Peter-Paul Kint; Patrick W Serruys
Journal:  J Thromb Thrombolysis       Date:  2009-11       Impact factor: 2.300

Review 9.  Platelet thrombin receptor antagonism and atherothrombosis.

Authors:  Dominick J Angiolillo; Davide Capodanno; Shinya Goto
Journal:  Eur Heart J       Date:  2009-11-30       Impact factor: 29.983

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.